미국의 아르테미신산 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 부문별 예측(2025-2033년)

U.S. Artemisinic Acid Market Summary

The U.S. artemisinic acid market size was estimated at USD 236.6 million in 2024 and is projected to reach USD 367.7 million by 2033, growing at a CAGR of 5.0% from 2025 to 2033. The primary factors driving the U.S. artemisinic acid market include an increase in malaria cases connected to international travel, the rising global resistance to traditional antimalarials, government-supported stockpiling initiatives, and expanded research and development in semi-synthetic production methods.

The rise of Plasmodium falciparum strains resistant to traditional antimalarial drugs in Africa and Southeast Asia is prompting healthcare providers and policymakers to prioritize access to fast-acting artemisinin-based treatments. As resistance patterns evolve, U.S. institutions increase their reliance on advanced artemisinic formulations, driving imports, R&D investment, and stockpiling of effective therapies to ensure readiness against more virulent malaria forms.

Furthermore, biotechnology innovations such as engineered Saccharomyces cerevisiae (yeast)-have enabled more stable and scalable production of artemisinic acid. This reduces reliance on agricultural sources such as Artemisia annua, vulnerable to climate and yield variability. As pharmaceutical companies adopt these methods, the U.S. market benefits from enhanced production reliability and cost-efficiency, supporting broader distribution and emergency preparedness.

U.S. Artemisinic Acid Market Report Segmentation

This report forecasts revenue growth at U.S. artemisinic acid market and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. artemisinic acid market report based on product.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Antimalarial Injections
• Antimalarial Tablets

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. U.S. Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Artemisinic Acid Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Artemisinic Acid Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
  • 3.3.3. Regulatory Framework

Chapter 4. U.S. Artemisinic Acid Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Artemisinic Acid Market: Product Movement Analysis
• 4.3. U.S. Artemisinic Acid Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
• 4.4. Antimalarial Tablets
  • 4.4.1. Antimalarial Tablets Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Antimalarial Injections
  • 4.5.1. Antimalarial Injections Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Market Participant Categorization
• 5.2. Company Market Position Analysis/ Heap Map Analysis
• 5.3. Company Profiles
  • 5.3.1. Sanofi
    • 5.3.1.1. Participant's Overview
    • 5.3.1.2. Financial Performance
    • 5.3.1.3. Product Benchmarking
    • 5.3.1.4. Strategic Initiatives
  • 5.3.2. KPC Pharmaceuticals, Inc.
    • 5.3.2.1. Participant's Overview
    • 5.3.2.2. Financial Performance
    • 5.3.2.3. Product Benchmarking
    • 5.3.2.4. Strategic Initiatives
  • 5.3.3. Guilin Pharmaceuticals Co,. Ltd.
    • 5.3.3.1. Participant's Overview
    • 5.3.3.2. Financial Performance
    • 5.3.3.3. Product Benchmarking
    • 5.3.3.4. Strategic Initiatives
  • 5.3.4. Calyx Chemicals and Pharmaceuticals Ltd.
    • 5.3.4.1. Participant's Overview
    • 5.3.4.2. Financial Performance
    • 5.3.4.3. Product Benchmarking
    • 5.3.4.4. Strategic Initiatives
  • 5.3.5. Novartis Pharmaceuticals Corporation
    • 5.3.5.1. Participant's Overview
    • 5.3.5.2. Financial Performance
    • 5.3.5.3. Product Benchmarking
    • 5.3.5.4. Strategic Initiatives
  • 5.3.6. Ipca Laboratories Inc.
    • 5.3.6.1. Participant's Overview
    • 5.3.6.2. Financial Performance
    • 5.3.6.3. Product Benchmarking
    • 5.3.6.4. Strategic Initiatives
  • 5.3.7. Cipla USA Inc.
    • 5.3.7.1. Participant's Overview
    • 5.3.7.2. Financial Performance
    • 5.3.7.3. Product Benchmarking
    • 5.3.7.4. Strategic Initiatives
  • 5.3.8. SHINPOONG CO. Ltd.
    • 5.3.8.1. Participant's Overview
    • 5.3.8.2. Financial Performance
    • 5.3.8.3. Product Benchmarking
    • 5.3.8.4. Strategic Initiatives